JP2021504382A5 - - Google Patents

Download PDF

Info

Publication number
JP2021504382A5
JP2021504382A5 JP2020529147A JP2020529147A JP2021504382A5 JP 2021504382 A5 JP2021504382 A5 JP 2021504382A5 JP 2020529147 A JP2020529147 A JP 2020529147A JP 2020529147 A JP2020529147 A JP 2020529147A JP 2021504382 A5 JP2021504382 A5 JP 2021504382A5
Authority
JP
Japan
Prior art keywords
organ
tissue
pharmaceutical composition
csf
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020529147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504382A (ja
JP7465210B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2018/051272 external-priority patent/WO2019104385A1/en
Publication of JP2021504382A publication Critical patent/JP2021504382A/ja
Publication of JP2021504382A5 publication Critical patent/JP2021504382A5/ja
Application granted granted Critical
Publication of JP7465210B2 publication Critical patent/JP7465210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020529147A 2017-11-29 2018-11-29 虚血-再灌流障害の治療又は予防方法 Active JP7465210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017904822A AU2017904822A0 (en) 2017-11-29 Method of treating or preventing ischemia-reperfusion injury
AU2017904822 2017-11-29
PCT/AU2018/051272 WO2019104385A1 (en) 2017-11-29 2018-11-29 Method of treating or preventing ischemia-reperfusion injury

Publications (3)

Publication Number Publication Date
JP2021504382A JP2021504382A (ja) 2021-02-15
JP2021504382A5 true JP2021504382A5 (enExample) 2022-01-06
JP7465210B2 JP7465210B2 (ja) 2024-04-10

Family

ID=66663689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529147A Active JP7465210B2 (ja) 2017-11-29 2018-11-29 虚血-再灌流障害の治療又は予防方法

Country Status (12)

Country Link
US (3) US20210179721A1 (enExample)
EP (1) EP3717011B1 (enExample)
JP (1) JP7465210B2 (enExample)
KR (1) KR102684627B1 (enExample)
CN (2) CN119792531A (enExample)
AU (1) AU2018377856B2 (enExample)
BR (1) BR112020010514A2 (enExample)
CA (1) CA3081770A1 (enExample)
DK (1) DK3717011T5 (enExample)
ES (1) ES2939461T3 (enExample)
PL (1) PL3717011T3 (enExample)
WO (1) WO2019104385A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2718326B1 (en) 2011-06-13 2020-08-19 CSL Limited Antibodies against g-csfr and uses thereof
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
BR112021010920A2 (pt) * 2018-12-04 2021-08-31 CSL Innovation Pty Ltd Método de tratamento de condições neutrofílicas
KR20220019806A (ko) * 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
IL325176A (en) 2023-07-05 2026-02-01 CSL Innovation Pty Ltd Methods for treating or preventing a complication of sickle cell disease
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU3691093A (en) 1992-04-14 1993-10-21 Hybritech Incorporated Methods of inhibiting the growth of multidrug resistant tumors
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
AUPM375194A0 (en) 1994-02-08 1994-03-03 Ludwig Institute For Cancer Research Cytokine receptor interactive molecules
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
CN1202246C (zh) 1998-04-08 2005-05-18 联邦科学和工业研究组织 获得修饰表型的方法和措施
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
JP2000319298A (ja) 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
AUPR544401A0 (en) 2001-06-04 2001-06-28 Bischof, Robert Juergen Animal model for allergy
US7501494B2 (en) 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
JP2006526414A (ja) 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ, インコーポレイテッド 脱免疫化抗cd3抗体
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のIgNARドメインに基づく結合成分
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP1924606A4 (en) * 2005-08-25 2010-01-13 Repair Technologies Inc DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
US8455435B2 (en) * 2006-04-19 2013-06-04 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia
AU2007271163B2 (en) 2006-07-06 2012-08-23 Merck Serono Sa CSF3R polypeptides and uses thereof
PL2056858T3 (pl) * 2006-08-11 2015-01-30 Csl Ltd Leczenie stanów chorobowych płuc
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
CL2008002782A1 (es) * 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
WO2011032204A1 (en) 2009-09-15 2011-03-24 Csl Limited Treatment of neurological conditions
US8968731B2 (en) 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
KR20130020765A (ko) 2010-02-16 2013-02-28 메디뮨 엘엘씨 Hsa-관련 조성물 및 사용방법
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires
RU2612884C2 (ru) 2010-04-02 2017-03-13 Курна, Инк. Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
WO2012058479A2 (en) 2010-10-27 2012-05-03 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type i (scr1)
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
EP2718326B1 (en) * 2011-06-13 2020-08-19 CSL Limited Antibodies against g-csfr and uses thereof
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9050305B2 (en) * 2012-03-29 2015-06-09 Chs Pharma, Inc. Treatment for ischemic stroke
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
KR101977449B1 (ko) 2013-11-01 2019-05-10 유니버시티에트 이 오슬로 알부민 변이체 및 이의 용도
UA117608C2 (uk) 2014-02-21 2018-08-27 Дженентек, Інк. Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
CN107106681B (zh) * 2014-11-17 2021-11-09 Csl有限公司 治疗或预防中风的方法
CA3020988A1 (en) * 2016-04-21 2017-10-26 Csl Limited Method of treating or preventing liver conditions
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
KR20190073917A (ko) 2017-12-19 2019-06-27 포항공과대학교 산학협력단 인터류킨-17 억제제 및 종양괴사인자-알파 억제제를 유효성분으로 포함하는 호중구성 폐 염증질환의 예방 또는 치료용 약학적 조성물
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
EP3876990A4 (en) 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
BR112021010920A2 (pt) 2018-12-04 2021-08-31 CSL Innovation Pty Ltd Método de tratamento de condições neutrofílicas
KR20220019806A (ko) 2019-06-12 2022-02-17 씨에스엘 이노베이션 피티와이 엘티디 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2021504382A5 (enExample)
Colvin et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association
EP3105252B1 (en) Bispecific antibodies for use in stem cell transplantation
US11945866B2 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
US20160184391A1 (en) Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP2021515566A5 (enExample)
JP2026053628A (ja) 抗炎症剤に連結されたecm親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
JP2019503361A (ja) がんを治療するための抗pd−1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
JP2022510634A (ja) 除去レジメンに抵抗性の遺伝的に改変されたhspc
JP2022545647A5 (enExample)
JP2015505244A (ja) 所望の特異性を有するモノクローナル自己抗体を提供する方法
JP2023519099A5 (enExample)
ES2341341T3 (es) Anticuerpos terapeuticos humanizados contra las isoformas cd45.
JP5688734B2 (ja) 移植片対腫瘍効果を保存した免疫学的再構築促進剤または感染症予防剤
US20240002526A1 (en) Uses of effector cell engaging molecules with moieties of differing potencies
JP2022528721A5 (enExample)
WO2023193662A1 (zh) 靶向bcma的嵌合抗原受体及其应用
TW202342507A (zh) 抗steap2嵌合抗原受體及其用途
US11104738B2 (en) Monoclonal antibodies to human FLT3/FLK2 receptor protein
Pescovitz The use of rituximab, anti‐CD20 monoclonal antibody, in pediatric transplantation
AU2023216348A1 (en) Anti-cd38 binding molecules and uses thereof
Zhong et al. Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases
WO1995013093A1 (en) Treatment of a patient prior to transplantation
KR20180108662A (ko) 변형된 이식편의 사전 사용에 의한 이식편 거부의 방지
Goker et al. Chimeric antigen receptor T cell treatment in hematologic malignancies